Overview

Inflammatory diseases – including psoriasis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and atherosclerosis – can be devastating and often life-threatening, are widespread and are currently not adequately treated or prevented.

VBL Therapeutics is committed to developing and bringing to patients first-in-class treatments for inflammatory diseases that will transform the way these conditions are treated and bring new hope to those facing these diseases.

Psoriasis Market

The estimated market for psoriasis biologics is currently valued at more than $2 billion and is projected to rise to more than $3 billion by 2011. While advances have been made in the treatment of psoriasis over the last decade with the advent of biologics, many of these treatments require subcutaneous injection by patients, often have serious side effects (e.g., infections, malignancies, progressive multifocal leukoencephalopathy), and are cost prohibitive for a number of patients and payers. There remains a significant, unmet need for a safe, effective, oral treatment option for psoriasis.

Rheumatoid Arthritis Market

More than two million Americans suffer from rheumatoid arthritis. The market for rheumatoid arthritis treatments is currently valued at more than $8 billion, and is expected to reach $10 billion by 2010. Rheumatoid arthritis is a disease in which the body’s immune system attacks the thin membrane that lines the joints, called the synovium, causing pain, swelling, inflammation, redness, heat and, if not stopped, joint destruction. Rheumatoid arthritis is a systemic disease that can affect other organs in the body, including the heart, putting patients with rheumatoid arthritis at high risk for heart disease.